Effects of losartan on low-density lipoprotein apheresis

Therapeutic Apheresis

Volumn 3, Issue 4, 1999, Pages 303-306

  Kojima, Shunichi ^a   Yoshitomi, Yuji ^a   Saotome, Masao ^a   Tanaka, Kyo E ^a   Shida, Mikio ^a   Kuramochi, Morio ^a  

^a SHIZUOKA MEDICAL CENTER   (Japan)

Author keywords

Angiotensin receptor antagonists; Bradykinin Angiotensin converting enzyme inhibitors; Low density lipoprotein apheresis

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMIDAPRIL; LOSARTAN; LOW DENSITY LIPOPROTEIN;

ADULT; APHERESIS; BLOOD PRESSURE REGULATION; CASE REPORT; CONFERENCE PAPER; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPOTENSION; ISCHEMIC HEART DISEASE; KALLIKREIN KININ SYSTEM; MALE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ALDOSTERONE; ANTIHYPERTENSIVE AGENTS; BRADYKININ; COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEINS, LDL; LOSARTAN; MALE; MIDDLE AGED; PLASMAPHERESIS; RENIN; TREATMENT OUTCOME;

EID: 0032752711     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-0968.1999.00195.x     Document Type: Conference Paper

References (12)

1. The SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992;327:669-77.
2. Kober L, Trop-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;333:1670-6.
3. Kojima S, Harada-Shiba M, Nomura S, Kimura G, Tsushima M, Kuramochi M, Yamamoto A, Omae T. Effect of nafamostat mesilate on bradykinin generation during low-density lipoprotein apheresis using a dextran sulfate cellulose column. ASAIO Trans 1991;37:644-8.
4. Olbricht CJ, Schaumann D, Fischer D. Anaphylactoid reactions, LDL apheresis with dextran sulphate, and ACE inhibitor. Lancet 1993;341:908-9.
5. Gradman AH, Arcuri KE, Goldberg AI, Ikeda LS, Nelson EB, Snavely DB, Sweet CS. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril malate in patients with essential hypertension. Hypertension 1995;25:1345-50.
6. Crozier I, Ikram H, Awan N, Cleland J, Stephen N, Dickstein K, Frey M, Young J, Klinger G, Makris L, Rucinska E. Losartan in heart failure: Hemodynamic effects and tolerability. Circulation 1995;91:691-7.
7. Tani N. Development of selective adsorbent and DS LDL apheresis system: Immobilized polyanions as LDL-specific adsorbent for DS LDL apheresis system. J Jpn Atheroscl Soc 1990;18:173-81.
8. Kojima S, Ogi M, Yoshitomi Y, Kuramochi M, Ikeda J, Nakagawa M, Hatakeyama H. Changes in bradykinin and prostaglandin plasma levels during dextran-sulfated low-density-lipoprotein apheresis. Int J Artif Organs 1997;20:178-83.
9. Kojima S, Ogi M, Yoshitomi Y, Iimuro M, Yaguchi Y, Iida T, Kuramochi M. A possible mechanism of hypotension during LDL apheresis in patients taking ACE inhibitors. Jpn J Apheresis 1997;16:250-1.
10. Elicio N, Bertolini S, Garbarini R, Nardiello G, Elicio A, Aimale V. LDL apheresis with dextran sulfate and angiotensin receptor antagonist Losartan. Artif Organs 1997;27:334-5.
11. Pintus S, Pintus P, Maxia P, Anedda S. Use of losartan in FH patients during treatment with DSC-LDL apheresis. J Clin Apheresis 1997;12:156.
12. Siragy HM, Jaffa AA, Margolius HS, Carey RM. Renin-angiotensin system modulates renal bradykinin production. Am J Physiol 1996;271:1090-5.